<DOC>
	<DOCNO>NCT01469078</DOCNO>
	<brief_summary>The purpose study assess Pharmakokinetic property iron isomaltoside 1000 ( Monofer® ) dose 100 mg , 200 mg 500 mg subject Stage 5 Chronic Kidney Disease Dialysis Therapy ( CKD-5D ) .</brief_summary>
	<brief_title>Open-label Pharmacokinetic Study Iron Isomaltoside 1000 ( Monofer® ) Administered Single Bolus Injections Subjects With Stage 5 Chronic Kidney Disease Dialysis Therapy ( CKD-5D )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Men woman , age 18 year . 2 . Weight 50 kg . 3 . Subjects diagnose CKD5D dialysis therapy least 90 day prior inclusion . 4 . Serum ferritin ≤ 800 ng/mL . 5 . Transferrin Saturation ≤ 35 % . 6 . Life expectancy beyond 12 month Principal Investigator 's judgement . 7 . Hb concentration ≥10.0 g/dL ≤12.5 g/dL Screening Visit 1a Screening Visit 1b ( Screening Visit 1a Visit 1b must separate least 1 week ) . 8 . Erythropoiesis Stimulating Agent ( ESA ) treatment ( kept constant study period 4 week prior inclusion one miss dose allow preentry period ) . 9 . Subjects maintenance iron therapy average iron administration ≤ 100 mg/week 4 week prior inclusion willingness switch investigational product . 10 . Willingness ability participate inform consent ( include HIPAA , applicable ) . 1 . Anemia cause primarily factor renal related anemia . 2 . Iron overload disturbance utilization iron ( e.g . hemochromatosis hemosiderosis ) . 3 . Difference Hb ≥ 1.0 g/dL Screening Visits 1a 1b . 4 . Known hypersensitivity excipients investigational drug product . 5 . Subjects history multiple allergy . 6 . Decompensated liver cirrhosis history hepatitis B C [ Alanine Aminotransferase ( ALT ) &gt; 3 time upper limit normal ] . 7 . Acute chronic infection ( assessed clinical investigator judgment ) , support White Blood Cells ( WBC ) CReactive Protein ( CRP ) . 8 . Rheumatoid arthritis symptom sign active joint inflammation . 9 . Pregnant nursing woman . 10 . Women child bear potential use safe contraceptive method ( e.g . intrauterine device , oral contraceptive surgically sterilize ) plan become pregnant within study period . 11 . Blood transfusion within previous 12 week . 12 . Planned elective surgery study significant blood loss expect . 13 . Participation clinical trial within 3 month prior screen . 14 . Untreated Vitamin B12 folate deficiency . 15 . Any medical condition , opinion Principal Investigator , may cause subject unsuitable completion study place subject potential risk study . Examples include Uncontrolled Hypertension , Unstable Ischemic Heart Disease Uncontrolled Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CKD stage 5</keyword>
	<keyword>Iron deficiency</keyword>
</DOC>